Target intelligence / Profile preview

Interleukin-6 receptor subunit beta (gp130) (IL6ST)

Target
IL6ST
Molecular classification
Receptor, Type I cytokine receptor, Single-pass type I membrane protein
01

Overview

Interleukin-6 receptor subunit beta (gp130), encoded by the IL6ST gene, is a ubiquitously expressed transmembrane glycoprotein that serves as the shared signal-transducing subunit for the interleukin-6 (IL-6) family of cytokines, including IL-6, IL-11, leukemia inhibitory factor (LIF), oncostatin M (OSM), and ciliary neurotrophic factor (CNTF). Upon cytokine binding to their specific alpha-receptor subunits, gp130 undergoes homodimerization or heterodimerization, which activates associated Janus kinases (JAKs) and subsequently phosphorylates downstream signal transducer and activator of transcription (STAT) proteins, particularly STAT3, as well as the MAPK and PI3K/Akt pathways. This signaling cascade plays a critical role in regulating immune responses, hematopoiesis, cell proliferation, survival, and tissue regeneration. Aberrant activation of gp130 signaling is strongly implicated in chronic inflammatory diseases, autoimmune disorders (such as rheumatoid arthritis and inflammatory bowel disease), and various cancers, where it drives tumor growth, metastasis, and chemoresistance. Consequently, gp130 has emerged as a highly attractive therapeutic target. Therapeutic strategies include the selective blockade of IL-6 trans-signaling using the soluble gp130-Fc fusion protein olamkicept, as well as small-molecule inhibitors like bazedoxifene and SC144 that directly disrupt gp130 dimerization and downstream STAT3 activation.

Other names
gp130Interleukin-6 signal transducerCD130CDw130IL-6 receptor subunit betaIL-6R subunit betaIL-6R-betaIL-6RBMembrane glycoprotein 130
02

Mechanism of action

Inhibition of gp130 homodimerization and heterodimerization, selective blockade of IL-6 trans-signaling, and suppression of downstream JAK/STAT3 signaling.

03

Biological functions

Signal transductionImmune responseCell proliferationApoptosisHematopoiesisInflammationEmbryonic development
04

Disease associations

CancerInflammationAutoimmune diseaseCardiovascular diseaseOsteoporosis
05

Safety considerations

ImmunosuppressionIncreased risk of infectionElevated liver enzymesHyperuricemiaBilirubinuriaNeutropeniaThrombocytopeniaGastrointestinal perforationImpaired wound healing
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

STAT3 phosphorylation (p-STAT3)gp130 phosphorylation (p-gp130)IL-6 levelsSoluble IL-6 receptor (sIL-6R) levelsC-reactive protein (CRP)Fecal calprotectin

Beyond the preview

Go deeper on Interleukin-6 receptor subunit beta (gp130) (IL6ST).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Interleukin-6 receptor subunit beta (gp130) (IL6ST).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call